Dr. Alistair Smith, Avacta Group PLC says the company is focused on two ways that would generate value for shareholders – Taking assets through into the clinical phases and to develop more novel assets which would be regarded as valuable and licensable by the Pharma companies. Smith also updates viewers about “excellent” results from the latest study of its Affimer technology and the significant growth in the number of partners worldwide in order to exploit the therapeutic and diagnostic potential of Affimer technology.

свернуть